KM Pharmaceutical Considers Selling Seoul Sales Office to Secure Growth Investment Funds Through Asset Efficiency

KM Pharmaceutical, known for its 'Pororo Toothpaste,' is considering the sale of its Seoul sales office building as part of its efforts to enhance asset efficiency and invest in future growth. If the sale is completed, the secured funds will be used to expand production facilities, invest in research and development (R&D), and pursue new business initiatives, with the goal of strengthening corporate competitiveness.

On July 1, KM Pharmaceutical announced that it is reviewing the sale of its Seoul sales office building, located near the Magok District in Seoul, from multiple perspectives to enhance its corporate value.

The property under consideration is a four-story building situated on a major road near Yangcheon Hyanggyo Station on Seoul Subway Line 9. The building has a land area of 445 square meters and a total floor area of 823 square meters. According to the market, the estimated sale value is assessed to be around 15 billion to 20 billion won.

The industry is focusing on the fact that this planned sale is more than a simple real estate disposal; it is viewed as a strategy to improve the company’s financial structure by utilizing owned assets. If the sale is completed, a gain on asset disposal is expected to occur due to the difference between the book value and the actual transaction price, which is anticipated to increase non-operating income and improve net profit.

In particular, considering KM Pharmaceutical’s current corporate size, some analysts suggest that this asset securitization could be a key event capable of bringing financial changes. If the sale price significantly exceeds the book value, the improvement in financial statements is expected to be even greater.

KM Pharmaceutical currently has its headquarters and Production Plants 1 and 2 located in Pyeongtaek, Gyeonggi Province. Therefore, if the sale of the Seoul sales office building proceeds, the company is expected to streamline operations by integrating sales functions and production bases around Pyeongtaek.

A source in the investment banking (IB) sector commented, "If the real estate sale is successful, it could have a positive effect in terms of improving the company’s financial structure," adding, "It is also important that the secured funds could be used for investments in production facilities, research and development, and expansion into new businesses."

A KM Pharmaceutical representative stated, "The sale of the building has not yet been finalized, but we are reviewing operational efficiency centered on the Pyeongtaek headquarters and production plants," adding, "If the sale proceeds in the future, the proceeds will be used as funds for investment in production facilities, research and development (R&D), and expansion into new businesses."

Through the review of the Seoul sales office building sale, KM Pharmaceutical aims to maximize the utilization of its assets and, based on the resources that can be secured, strengthen production competitiveness and lay the foundation for mid- to long-term growth.

This content was produced with the assistance of AI translation services.